Welcome to BioSeeker Group!

Commercializing Peptides in Oncology: A Decision Support Tool for Optimizing the Pipeline

Additional Information

Published Date Jun 24, 2010
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 596
PDF Fact Sheet View Fact Sheet for the report Commercializing Peptides in Oncology: A Decision Support Tool for Optimizing the Pipeline in PDF
Format PDF
Publisher BioSeeker Group
Product Line View All Available Cancer Highlights Reports

Availability: In stock

$2,450.00

Quick Overview

This report identifies the competitive terrain for cancer therapeutic peptides to be wide open from a compound perspective and the opportunity for peptide drugs to challenge other biologicals such as antibodies is real and significant.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Commercializing Peptides in Oncology: A Decision Support Tool for Optimizing the Pipeline.

    To find out more about Commercializing Peptides in Oncology: A Decision Support Tool for Optimizing the Pipeline, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Commercializing Peptides in Oncology: A Decision Support Tool for Optimizing the Pipeline is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This report comprises defined and up to date development strategies for 145 cancer peptide drugs within the portfolio of 103 investigators, from Ceased to Marketed. The report extensively analyses 125 identified targets of peptide drugs, organized into 103 drug target strategies, and assesses them in 52 different cancer indications.

The discovery of new cancer therapeutics has seen a significant shift towards biologicals as an alternative to small molecule drugs. Alternative binding peptide molecules, derived from combinatorial scaffold libraries, are now challenging traditional antibodies. This report identifies the competitive terrain for cancer therapeutic peptides to be wide open from a compound perspective and the opportunity for peptide drugs to challenge other biologicals such as antibodies is real and significant.

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies
* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for any cancer peptide drug to ensure that the optimal market conditions exist by the time the product is commercialized.

1 Executive Summary 3
2 About Cancer Highlights™ 4
2.1 Cancer Focus Areas 4
2.2 Subscribe Today and Start Saving 5
2.2.1 Type of License 5
2.3 BioSeeker Group’s Oncology Team 5
3 Methodology 6
3.1 Cancer Highlights’™ Five Pillar Assessment 6
4 Table of Contents 8
4.1 List of Figures 17
4.2 List of Tables 17
5 Introduction 24
5.1 The Scope of this Report 24
5.2 The Competitive Advantage and Disadvantage of Peptide Drugs 26
5.3 Definitions 28
5.4 Abbreviations 28
6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment 29
6.1 Drug Repositioning in Oncology 29
6.2 Introduction to Peptide Therapeutic Targets in Oncology 30
6.2.1 Catalytic Activity Targets 33
6.2.2 Chaperone Activity Targets 34
6.2.3 Chemokine Activity Targets 36
6.2.4 Cytokine Activity Targets 40
6.2.5 Cytoskeletal Protein Binding Targets 42
6.2.6 DNA Binding Targets 43
6.2.7 DNA Topoisomerase Activity Targets 44
6.2.8 G-protein Coupled Receptor Activity Targets 45
6.2.9 Growth Factor Activity Targets 63
6.2.10 Heat Shock Protein Activity Targets 64
6.2.11 Hormone Activity Targets 65
6.2.12 Isomerase Activity Targets 66
6.2.13 Kinase Activity Targets 67
6.2.14 Kinase Binding Targets 69
6.2.15 Kinase Regulator Activity Targets 70
6.2.16 Ligand-dependent Nuclear Receptor Activity Targets 72
6.2.17 Metallopeptidase Activity Targets 75
6.2.18 Molecular Function Unknown Targets 81
6.2.19 Oxidoreductase Activity Targets 87
6.2.20 Peptide Hormone Targets 88
6.2.21 Protease Inhibitor Activity Targets 90
6.2.22 Protein Binding Targets 91
6.2.23 Protein Serine/Threonine Kinase Activity Targets 93
6.2.24 Protein Tyrosine/Serine/Threonine Phosphatase Activity Targets 103
6.2.25 Protein-tyrosine Kinase Activity Targets 104
6.2.26 Receptor Activity Targets 107
6.2.27 Receptor Binding Targets 130
6.2.28 Receptor Signaling Complex Scaffold Activity Targets 132
6.2.29 Receptor Signaling Protein Serine/Threonine Kinase Activity Targets 135
6.2.30 Receptor Signaling Protein Serine/Threonine Kinase Activity Targets 136
6.2.31 RNA Binding Targets 137
6.2.32 RNA-directed DNA Polymerase Activity Targets 138
6.2.33 Serine-type Peptidase Activity Targets 139
6.2.34 Signal Transducer Activity Targets 142
6.2.35 Structural Molecule Activity Targets 144
6.2.36 T Cell Receptor Activity Targets 145
6.2.37 Transcription Factor Activity Targets 146
6.2.38 Transcription Regulator Activity Targets 153
6.2.39 Transferase Activity Targets 154
6.2.40 Transmembrane Receptor Activity Targets 155
6.2.41 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets 159
6.2.42 Ubiquitin-specific Protease Activity Targets 170
6.2.43 Virus Targets 171
6.3 The Cancer Genome Project and Cancer Peptide Targets 172
6.3.1 Cancer Peptide Drug Targets Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer 172
6.4 Structure-based Drug Design in Cancer Peptide Therapeutics is Stimulated by Available Structure Data on Biological Targets 177
6.5 Target-Target Interactions among Identified Targets of Peptide Drugs 179
6.6 The Drug-Target Interactome 183
6.7 Protein Expression Levels of Identified Targets of Cancer Peptide Drugs 187
6.8 Pathway Assessment of Peptide Therapeutic Targets in Oncology 190
6.8.1 Tools for Analysis of Cancer Pathways 191
6.8.2 Pathway Assessment 192
7 Emerging New Products to Established Ones: Drug Target Strategies of Peptides by their Highest Stage of Development in Oncology 220
7.1 Drug Target Strategies of Terminated Peptide Drugs in Oncology 222
7.2 Marketed: New and Unique Drug Target Strategies of Peptide Drugs in Oncology 225
7.3 Phase III Clinical Development: New and Unique Drug Target Strategies of Peptide Drugs in Oncology 227
7.4 Phase II Clinical Development: New and Unique Drug Target Strategies of Peptide Drugs in Oncology 228
7.5 Phase I Clinical Development: New and Unique Drug Target Strategies of Peptide Drugs in Oncology 230
7.6 Preclinical Development: New and Unique Drug Target Strategies of Peptide Drugs in Oncology 232
7.7 No Development Data: New and Unique Drug Target Strategies of Peptide Drugs in Oncology 235
7.8 Development Profiles of All Peptide Drugs in Oncology 236
7.9 The Competition Through Close Mechanistic Approximation of Cancer Peptide Drugs 245
8 Selecting Cancer Indications for Peptide Drugs 247
8.1 Acute Myelogenous Leukemia 250
8.2 Benign prostatic hyperplasia 251
8.3 Bladder Cancer 252
8.4 Bone Cancer 253
8.5 Brain Cancer 254
8.6 Breast Cancer 255
8.7 Cancer Diagnosis 257
8.8 Carcinoid 258
8.9 Carcinoid Syndrome 258
8.10 Cervical Cancer 258
8.11 Chemotherapy-induced Alopecia 259
8.12 Chemotherapy-induced Anemia 259
8.13 Chemotherapy-induced Bone Marrow Injury (general) 260
8.14 Chemotherapy-induced GI Injury 261
8.15 Chemotherapy-induced Injury (general) 262
8.16 Chemotherapy-induced Mucositis 262
8.17 Chemotherapy-induced Nausea and Vomiting 264
8.18 Chemotherapy-induced Neutropenia 264
8.19 Chemotherapy-induced Thrombocytopenia 264
8.20 Chronic Lymphocytic Leukemia 265
8.21 Chronic Myelogenous Leukemia 266
8.22 Colorectal Cancer 267
8.23 Endometrial Cancer 269
8.24 Fallopian Tube Cancer 269
8.25 Gastrointestinal Cancer (general) 270
8.26 Gastrointestinal Stomach Cancer 271
8.27 Head and Neck Cancer 272
8.28 Liver Cancer 273
8.29 Lung Cancer (general) 275
8.30 Lymphoma (general) 276
8.31 Melanoma 277
8.32 Mesothelioma 279
8.33 Myelodysplastic Syndrome 280
8.34 Myeloma 281
8.35 Myoma 282
8.36 Neuroblastoma 282
8.37 non-Hodgkin’s Lymphoma 282
8.38 Non-Small Cell Lung Cancer 283
8.39 Oesophageal Cancer 285
8.40 Ovarian Cancer 286
8.41 Pancreatic Cancer 288
8.42 Peritoneal Cancer 289
8.43 Prostate Cancer 290
8.44 Renal Cancer 293
8.45 Sarcoma (general) 294
8.46 Small Cell Lung Cancer 295
8.47 Soft Tissue Sarcoma 296
8.48 Solid Tumor 297
8.49 Squamous Cell Cancer 297
8.50 Thyroid Cancer 297
8.51 Unspecified 298
8.52 Vaccine adjunct 300
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Peptide Drug Pipeline in Oncology by Investigator 301
9.1 Competitive Fall-Out Assessment 301
9.2 Changes in the Competitive Landscape: M&A, Bankruptcy and Name Change 303
9.3 Abbott 304
9.4 Acceleron Pharma 308
9.5 Aeterna Zentaris 311
9.6 Affymax 317
9.7 Aileron Therapeutics 321
9.8 Allostera 323
9.9 Ambrilia Biopharma 325
9.10 Amgen 328
9.11 Anchor Therapeutics 332
9.12 AngioChem 335
9.13 Angstrom Pharmaceuticals 338
9.14 AplaGen Biopharmaceuticals 341
9.15 ApopLogic Pharmaceuticals 343
9.16 Apthera 346
9.17 Ardana 349
9.18 Ark Therapeutics 353
9.19 Attenuon 355
9.20 AVI BioPharma 358
9.21 Baxter International 361
9.22 BioAlliance Pharma 364
9.23 Biokine Therapeutics 366
9.24 CanBas 369
9.25 Cancer Innovations 372
9.26 Cancer Research Technology 375
9.27 CDG Therapeutics 381
9.28 Celecure 384
9.29 Celldex Therapeutics 386
9.30 Chemokine Therapeutics 389
9.31 Compugen 392
9.32 Curaxis Pharmaceutical 394
9.33 Cyclacel 397
9.34 Daiichi Sankyo 399
9.35 Dendreon 401
9.36 Diatos 404
9.37 Eli Lilly 407
9.38 Endo Pharmaceuticals 410
9.39 Enkam Pharmaceuticals 413
9.40 EntreMed 416
9.41 Esperance Pharmaceuticals 419
9.42 Generex 421
9.43 GENova Biotherapeutics 423
9.44 Genzyme 425
9.45 GlaxoSmithKline 428
9.46 Gliknik 431
9.47 GP Pharm 433
9.48 Gryphon Therapeutics 437
9.49 Hoffmann-La Roche 439
9.50 ImmuneRegen Biosciences 442
9.51 ImmunoCellular Therapeutics 444
9.52 Immunomedics 446
9.53 Immunotope 448
9.54 ImmuPharma 451
9.55 Innovive 453
9.56 ISA Pharmaceuticals 456
9.57 Johnson & Johnson 459
9.58 Karyon-CTT 463
9.59 Lee’s Pharmaceutical 466
9.60 Mannkind 469
9.61 Marillion Pharmaceuticals 471
9.62 MBiotec 474
9.63 Mediolanum 476
9.64 MolMed 479
9.65 Nektar Therapeutics 483
9.66 Nemod Biotherapeutics 486
9.67 Nidus Laboratories 489
9.68 Non-industrial Sources 492
9.69 Norwood Abbey 498
9.70 Novartis 501
9.71 NPS Pharmaceuticals 504
9.72 OncoTherapy Science 507
9.73 Oncothyreon 510
9.74 Pepscan Therapeutics 514
9.75 PepTx 516
9.76 PharmaGap 519
9.77 Pharmexa 522
9.78 Q Chip 525
9.79 QLT 528
9.80 Raptor Pharmaceutical 531
9.81 Receptor BioLogix 535
9.82 SciClone Pharmaceuticals 538
9.83 Serometrix 541
9.84 Shire 543
9.85 Soligenix 546
9.86 Spectrum Pharmaceuticals 549
9.87 Thallion Pharmaceuticals 551
9.88 Therion Biologics 554
9.89 Theryte 557
9.90 Tigris Pharmaceuticals 560
9.91 Unigene 562
9.92 United Biomedical 565
9.93 Vaxil BioTherapeutics 567
9.94 Vaxon Biotech 570
9.95 VaxOnco 573
9.96 Vical 576
9.97 Xigen 579
9.98 Zealand Pharmaceuticals 581
9.99 Zelos Therapeutics 584
9.100 Zensun 586
10 Disclaimer 588
11 Drug Index 589
12 Company Index 593

4.1 List of Figures
Figure 1: Visualization of Target-Target Interactions among Targets of Peptide Drugs in Oncology 182
Figure 2: The Drug-Target Interactions of Cancer Peptide Drugs - Large Cluster 184
Figure 3: The Drug-Target Interactions of Cancer Peptide Drugs - Smaller Clusters 185
Figure 4: Head-to-Head Targeting Interactions of Cancer Peptide Drugs 186

4.2 List of Tables
Table 1: Cancer Highlights’™ Five Pillar Assessment 6
Table 2: Breakdown of the Included Cancer Peptide Pipeline by Stage of Development 24
Table 3: Head to Head Target Competition among Cancer Peptide Drugs 24
Table 4: Overview of Drug Target Strategy Themes 30
Table 5: Terminally Ceased Targets of Peptide Drugs in Oncology 31
Table 6: Drug Targets of Peptide Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census 173
Table 7: Identity of Cancer Peptide Drug Targets with Available Biological Structures 177
Table 8: Number of Target-Target Interactions among Targets of Peptide Drugs in Oncology 179
Table 9: Available Protein Expression Profiles of Peptide Drug Targets 187
Table 10: Pathway Summary 192
Table 11: Drug Targets without any Identified Assigned Pathways 192
Table 12: Pathway Profiles According to BioCarta of Peptide Drug Targets in Oncology 194
Table 13: Pathway Profiles According to KEGG of Peptide Drug Targets in Oncology 205
Table 14: Pathway Profiles According to NetPath of Peptide Drug Targets in Oncology 217
Table 15: Number of Drug Target Strategies by their Highest Developmental Stage and Uniqueness 220
Table 16: Top Competitive Target Strategies of Peptide Drugs in Oncology 221
Table 17: Target Strategies of Terminated Peptide Drugs in Oncology 223
Table 18: New and Unique Target Strategies of Marketed Peptide Drugs in Oncology 225
Table 19: The Competition Through Close Mechanistic Approximation Between Marketed Peptide Drugs in Cancer 226
Table 20: New and Unique Target Strategies in Phase III Clinical Development of Peptide Drugs in Oncology 227
Table 21: The Competition Through Close Mechanistic Approximation Between Phase III Peptide Drugs in Cancer 227
Table 22: New and Unique Target Strategies in Phase II Clinical Development of Peptide Drugs in Oncology 228
Table 23: The Competition Through Close Mechanistic Approximation Between Phase II Peptide Drugs in Cancer 229
Table 24: New and Unique Target Strategies in Phase I Clinical Development of Peptide Drugs in Oncology 230
Table 25: The Competition Through Close Mechanistic Approximation Between Phase I Peptide Drugs in Cancer 231
Table 26: New and Unique Target Strategies in Preclinical Development of Peptide Drugs in Oncology 232
Table 27: The Competition Through Close Mechanistic Approximation Between Preclinical Peptide Drugs in Cancer 233
Table 28: New and Unique Target Strategies in Unknown Developmental Stage of Peptide Drugs in Oncology 235
Table 29: The Competition Through Close Mechanistic Approximation Between Peptide Drugs with No Developmental Data in Cancer 235
Table 30: The Progression, Maturity and Competitive Comparison of Target Strategies of Peptide Drugs in Oncology 236
Table 31: The Competition Through Close Mechanistic Approximation Among All Peptide Drugs in Cancer 245
Table 32 Indication Selection Competitive Summary of Peptide Drugs by Cancer Indication 248
Table 33: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Acute Myelogenous Leukemia 250
Table 34: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Benign prostatic hyperplasia 251
Table 35: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Bladder Cancer 252
Table 36: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Bone Cancer 253
Table 37: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Brain Cancer 254
Table 38: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Breast Cancer 255
Table 39: The Competition through Close Mechanistic Approximation between Breast Cancer Drugs 256
Table 40: Target Strategy Development Profiles of Peptide Compounds for Cancer Diagnosis 257
Table 41: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Carcinoid 258
Table 42: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Carcinoid Syndrome 258
Table 43: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Cervical Cancer 258
Table 44: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Chemotherapy-induced Alopecia 259
Table 45: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Chemotherapy-induced Anemia 259
Table 46: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Chemotherapy-induced Bone Marrow Injury (general) 260
Table 47: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Chemotherapy-induced GI Injury 261
Table 48: The Competition through Close Mechanistic Approximation between Chemotherapy-induced GI Injury Drugs 261
Table 49: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Chemotherapy-induced Injury (general) 262
Table 50: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Chemotherapy-induced Mucositis 262
Table 51: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Chemotherapy-induced Nausea and Vomiting 264
Table 52: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Chemotherapy-induced Neutropenia 264
Table 53: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Chemotherapy-induced Thrombocytopenia 264
Table 54: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Chronic Lymphocytic Leukemia 265
Table 55: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Chronic Myelogenous Leukemia 266
Table 56: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Colorectal Cancer 267
Table 57: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Endometrial Cancer 269
Table 58: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Fallopian Tube Cancer 269
Table 59: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Gastrointestinal Cancer (general) 270
Table 60: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Gastrointestinal Stomach Cancer 271
Table 61: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Head and Neck Cancer 272
Table 62: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Liver Cancer 273
Table 63: The Competition through Close Mechanistic Approximation between Liver Cancer Drugs 274
Table 64: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Lung Cancer (general) 275
Table 65: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Lymphoma (general) 276
Table 66: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Melanoma 277
Table 67: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Mesothelioma 279
Table 68: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Myelodysplastic Syndrome 280
Table 69: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Myeloma 281
Table 70: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Myoma 282
Table 71: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Neuroblastoma 282
Table 72: Target Strategy Development Profiles of Peptide Drugs for the Treatment of non-Hodgkin’s Lymphoma 282
Table 73: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Non-Small Cell Lung Cancer 283
Table 74: The Competition through Close Mechanistic Approximation between Non-Small Cell Lung Cancer Drugs 284
Table 75: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Oesophageal Cancer 285
Table 76: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Ovarian Cancer 286
Table 77: The Competition through Close Mechanistic Approximation between Ovarian Cancer Drugs 287
Table 78: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Pancreatic Cancer 288
Table 79: The Competition through Close Mechanistic Approximation between Pancreatic Cancer Drugs 289
Table 80: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Peritoneal Cancer 289
Table 81: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Prostate Cancer 290
Table 82: The Competition through Close Mechanistic Approximation between Prostate Cancer Drugs 291
Table 83: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Renal Cancer 293
Table 84: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Sarcoma (general) 294
Table 85: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Small Cell Lung Cancer 295
Table 86: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Soft Tissue Sarcoma 296
Table 87: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Solid Tumor 297
Table 88: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Squamous Cell Cancer 297
Table 89: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Thyroid Cancer 297
Table 90: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Unspecified 298
Table 91: The Competition through Close Mechanistic Approximation between Unspecified Cancer Indication Drugs 300
Table 92: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Vaccine adjunct 300
Table 93: Example of a Competitive Fall-Out Table (Modified, Gonadotropin-releasing hormone receptor) 302
Table 94: Summary Table of Changes in the Competitive Landscape of Peptide Drug Development in Oncology 303
Table 95: Abbott’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 304
Table 96: Acceleron Pharma’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 308
Table 97: Aeterna Zentaris’ Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 311
Table 98: Affymax’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 317
Table 99: Aileron Therapeutics’ Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 321
Table 100: Allostera’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 323
Table 101: Ambrilia Biopharma’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 325
Table 102: Amgen’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 328
Table 103: Anchor Therapeutics’ Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 332
Table 104: AngioChem’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 335
Table 105: Angstrom Pharmaceuticals’ Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 338
Table 106: AplaGen Biopharmaceuticals’ Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 341
Table 107: ApopLogic Pharmaceuticals’ Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 343
Table 108: Apthera’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 346
Table 109: Ardana’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 349
Table 110: Ark Therapeutics’ Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 353
Table 111: Attenuon’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 355
Table 112: AVI BioPharma’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 358
Table 113: Baxter International’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 361
Table 114: BioAlliance Pharma’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 364
Table 115: Biokine Therapeutics’ Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 366
Table 116: CanBas’ Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 369
Table 117: Cancer Innovations’ Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 372
Table 118: Cancer Research Technology’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 375
Table 119: CDG Therapeutics’ Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 381
Table 120: Celecure’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 384
Table 121: Celldex Therapeutics’ Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 386
Table 122: Chemokine Therapeutics’ Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 389
Table 123: Compugen’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 392
Table 124: Curaxis Pharmaceutical’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 394
Table 125: Cyclacel’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 397
Table 126: Daiichi Sankyo’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 399
Table 127: Dendreon’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 401
Table 128: Diatos’ Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 404
Table 129: Eli Lilly’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 407
Table 130: Endo Pharmaceuticals’ Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 410
Table 131: Enkam Pharmaceuticals’ Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 413
Table 132: EntreMed’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 416
Table 133: Esperance Pharmaceuticals’ Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 419
Table 134: Generex’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 421
Table 135: GENova Biotherapeutics’ Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 423
Table 136: Genzyme’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 425
Table 137: GlaxoSmithKline’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 428
Table 138: Gliknik’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 431
Table 139: GP Pharm’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 433
Table 140: Gryphon Therapeutics’ Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 437
Table 141: Hoffmann-La Roche’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 439
Table 142: ImmuneRegen Biosciences’ Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 442
Table 143: ImmunoCellular Therapeutics’ Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 444
Table 144: Immunomedics’ Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 446
Table 145: Immunotope’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 448
Table 146: ImmuPharma’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 451
Table 147: Innovive’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 453
Table 148: ISA Pharmaceuticals’ Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 456
Table 149: Johnson & Johnson’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 459
Table 150: Karyon-CTT’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 463
Table 151: Lee’s Pharmaceutical’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 466
Table 152: Mannkind’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 469
Table 153: Marillion Pharmaceuticals’ Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 471
Table 154: MBiotec’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 474
Table 155: Mediolanum’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 476
Table 156: MolMed’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 479
Table 157: Nektar Therapeutics’ Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 483
Table 158: Nemod Biotherapeutics’ Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 486
Table 159: Nidus Laboratories’ Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 489
Table 160: Non-industrial Sources’ Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 492
Table 161: Norwood Abbey’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 498
Table 162: Novartis’ Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 501
Table 163: NPS Pharmaceuticals’ Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 504
Table 164: OncoTherapy Science’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 507
Table 165: Oncothyreon’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 510
Table 166: Pepscan Therapeutics’ Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 514
Table 167: PepTx’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 516
Table 168: PharmaGap’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 519
Table 169: Pharmexa’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 522
Table 170: Q Chip’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 525
Table 171: QLT’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 528
Table 172: Raptor Pharmaceutical’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 531
Table 173: Receptor BioLogix’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 535
Table 174: SciClone Pharmaceuticals’ Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 538
Table 175: Serometrix’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 541
Table 176: Shire’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 543
Table 177: Soligenix’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 546
Table 178: Spectrum Pharmaceuticals’ Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 549
Table 179: Thallion Pharmaceuticals’ Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 551
Table 180: Therion Biologics’ Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 554
Table 181: Theryte’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 557
Table 182: Tigris Pharmaceuticals’ Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 560
Table 183: Unigene’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 562
Table 184: United Biomedical’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 565
Table 185: Vaxil BioTherapeutics’ Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 567
Table 186: Vaxon Biotech’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 570
Table 187: VaxOnco’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 573
Table 188: Vical’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 576
Table 189: Xigen’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 579
Table 190: Zealand Pharmaceuticals’ Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 581
Table 191: Zelos Therapeutics’ Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 584
Table 192: Zensun’s Featured Peptide Drug Pipeline in Oncology and Competitive Fall-Out 586

This report includes 103 investigators plus their collaborators:
Abbott
Acceleron Pharma
Aeterna Zentaris
Affymax
Aileron Therapeutics
Allostera
Ambrilia Biopharma
Amgen
Anchor Therapeutics
AngioChem
Angstrom Pharmaceuticals
AplaGen Biopharmaceuticals
ApopLogic Pharmaceuticals
Apthera
Ardana
Ark Therapeutics
Attenuon
AVI BioPharma
Baxter International
BioAlliance Pharma
Biokine Therapeutics
CanBas
Cancer Innovations
Cancer Research Technology
CDG Therapeutics
Celecure
Celldex Therapeutics
Chemokine Therapeutics
Compugen
Curaxis Pharmaceutical
Cyclacel
Daiichi Sankyo
Dendreon
Diatos
Eli Lilly
Endo Pharmaceuticals
Enkam Pharmaceuticals
EntreMed
Esperance Pharmaceuticals
Generex
GENova Biotherapeutics
Genzyme
GlaxoSmithKline
Gliknik
GP Pharm
Gryphon Therapeutics
Hoffmann-La Roche
ImmuneRegen Biosciences
ImmunoCellular Therapeutics
Immunomedics
Immunotope
ImmuPharma
Innovive
ISA Pharmaceuticals
Johnson & Johnson
Karyon-CTT
Lee’s Pharmaceutical
Mannkind
Marillion Pharmaceuticals
MBiotec
Mediolanum
MolMed
Nektar Therapeutics
Nemod Biotherapeutics
Nidus Laboratories
Norwood Abbey
Novartis
NPS Pharmaceuticals
OncoTherapy Science
Oncothyreon
Pepscan Therapeutics
PepTx
PharmaGap
Pharmexa
Q Chip
QLT
Raptor Pharmaceutical
Receptor BioLogix
SciClone Pharmaceuticals
Serometrix
Shire
Soligenix
Spectrum Pharmaceuticals
Thallion Pharmaceuticals
Therion Biologics
Theryte
Tigris Pharmaceuticals
Unigene
United Biomedical
Vaxil BioTherapeutics
Vaxon Biotech
VaxOnco
Vical
Xigen
Zealand Pharmaceuticals
Zelos Therapeutics
Zensun
This report includes 145 cancer peptide drugs. From Ceased to Marketed.
A shortlist of drugs included are:
A6
abarelix
ABT-510
AEZS-108
AMG-386
angiopep+paclitaxel
CBP-501
cetrorelix acetate
deslorelin
E-75
GV-1001
Her-2/Neu peptides
histrelin
ISA-P53-01
leuprolide
leuprorelin
MKC-1106-MT
netupitant
NGR-TNF
OTS-102
ozarelix
pasireotide
PEP-223
rindopepimut
romiplostim
romurtide
sotatercept
Stimuvax
thymalfasin
tigapotide triflutate
VX-001

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Commercializing Peptides in Oncology: A Decision Support Tool for Optimizing the Pipeline.
    To find out more about Commercializing Peptides in Oncology: A Decision Support Tool for Optimizing the Pipeline, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Commercializing Peptides in Oncology: A Decision Support Tool for Optimizing the Pipeline is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Cancer Highlights' category:


Superficial Bladder Cancer - Current Mangement and Future Trends
Superficial bladder cancers (SBC) comprise tumours with low aggressiveness but a high recurrence rate as well as lesions with a high risk of progression. Learn More


Currently Druggable in Colorectal Cancer: A Drug Target Competitive Analysis
This report is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of colorectal cancer drugs. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Colorectal Cancer, Lung Cancer and Apoptosis
This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Lung Cancer and by the mechanism/target/effect of Apoptosis. Learn More


Target Atlas in Fallopian Tube Cancer: A Competitive Outlook
System Requirements - Operating system: Windows (2000/XP/Vista/7/8/10) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
- Browser Application (Internet Explorer)
- Internet access (to access related internet resources)
Learn More